Established in 1951, Gyma Laboratories of America connects pharmaceutical companies with the active ingredients, development partners, and regulatory support needed to move drugs from research toward market. The company has supplied APIs to the U.S. pharmaceutical industry for more than 70 years and now operates across North America, Europe, and Asia, with newer capabilities in biotechnology and mRNA development. Its work spans the drug life cycle, including support for more than 1,000 first-to-market APIs under ANDA filings since 1971.